DGX · Quest Diagnostics Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Organic requisition volume | 13% | Q2 2026 | — |
|
|
|||
| Requisition volume | 13.1% | Q2 2026 | — |
|
|
|||
| Adjusted diluted EPS non-GAAP | $2.5 | Three Months Ended March 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Diluted EPS (As reported) $2.24
+$0.04 Restructuring and integration charges
+$0.03 Other charges
+$0.05 Gains and losses on investments
+$0.25 Amortization expense
-$0.11 ETB
= Adjusted Diluted EPS $2.5
|
|||
| Adjusted operating income non-GAAP | $447M | Three Months Ended March 31, 2026 | — |
| Adjusted operating income as a percentage of net revenues non-GAAP | 15.4% | Three Months Ended March 31, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DGX
this stock
Quest Diagnostics Inc
|
$26.99B | +41.2% | +11.8% | 26.0 | 3.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$234.31B | +9.4% | +14.5% | 34.1 | 1.3% |
|
DHR
Danaher Corp /De/
|
$151.82B | -5.9% | +8.5% | 38.3 | 1.2% |
|
NTRA
Natera, Inc.
|
$48.75B | +47.7% | -2.8% | — | 3.0% |
|
A
Agilent Technologies, Inc.
|
$43.33B | +14.0% | +6.4% | 30.8 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DGX | +1.3% | +4.2% | +20.1% | +5.2% | +41.2% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +1.7% | -0.9% | +7.7% | +2.6% | +28.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.